Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab
Status:
Terminated
Trial end date:
2009-07-25
Target enrollment:
Participant gender:
Summary
Eligible patients must receive vinorelbine plus capecitabine, with or without trastuzumab,
until disease progression or unbearable toxicity. Cycles will be administered every 3
weeks.Human epidermal growth factor receptor 2 (HER2) status must be locally assessed by
immunohistochemistry (IHC). All 3+ patients are eligible. In 2+ patients, HER2 status must be
confirmed by fluorescence in situ hybridization (FISH).